OBJECTIVE: Insulin inhibition of insulin secretion has been described in normal lean subjects. In this study, we examined whether this phenomenon also occurs in the morbidly obese who often have severe peripheral insulin resistance. SUBJECTS: Twelve obese patients, normotolerant to glucose (8 Fa4 M, body mass index (BMI) 54.8 AE 2.5 kgam 2 , 39 y) and 16 lean control subjects (10 Fa6 M, BMI 22.0 AE 0.5 kgam 2 , 31 y). DESIGN AND MEASUREMENTS: An experimental study using various parameters, including an euglycemic hyperinsulinemic clamp (280 pmolaminam 2 of body surface), an oral glucose tolerance test (OGTT), electrical bioimpedance and indirect calorimetry. RESULTS: The obese subjects were insulin resistant (M 19.8 AE 1.6 vs 48.7 AE 2.6 mmolamin kg FFM, P`0.0001) and hyperinsulinemic in the fasted state and after glucose ingestion. Fasting plasma C-peptide levels (obese 1425 AE 131 pmolal vs lean 550 AE 63 pmolal; P`0.0001) decreased less during the clamp in the obese groups (À16.9 AE 6.9% vs À43.0 AE 5.6% relative to fasting values; P 0.007). In the lean group, the C-peptide decrease during the clamp (percentage variation) was related to insulin sensitivity, MaFFM (r 0.56, P 0.03), even after adjustment for the clamp glucose variation. CONCLUSION: We conclude that, in lean subjects, insulin inhibits its own secretion, and this may be related to insulin sensibility. This response is blunted in morbidly obese patients and may have a role in the pathogenesis of fasting hyperinsulinemia in these patients.
Introduction
Obesity is a risk factor in type 2 diabetes mellitus, 1, 2 hypertension and coronary heart disease. 3, 4 Hyperinsulinemia and insulin resistance are important early metabolic changes in the obese. 5, 6 The mechanism underlying this hyperinsulinemia is not known. Circulating insulin levels represent a balance between the rate of insulin secretion and its rate of metabolic clearance. The posthepatic metabolic clearance rate in obesity is generally normal, 7, 8 whereas the ef®ciency of hepatic insulin extraction is unclear. 9 ± 11 In addition, studies in vivo and in vitro have shown that insulin secretion is enhanced in obese individuals, and hypersecretion has been demonstrated in the fasting state, after glucose infusion or ingestion, and over 24 h on a mixed diet. 12 ± 14 Secretion is in turn regulated by complex stimulatory and inhibitory in¯uences on the b-cells. Among the inhibitory in¯uences is the still controversial question of a direct or indirect negative feedback of circulating insulin on b-cell secretion. Insulin feedback inhibition has been reported in normal humans under euglycemic conditions, 15 although this has not been observed in other studies. 16, 17 In obesity, the insulin resistance of peripheral tissues may be paralleled by resistance to the inhibitory effects of insulin on b-cells. Graves' disease is accompanied by peripheral insulin resistance and impaired insulin feedback, 18 whereas in type 2 diabetic patients the results are divergent. 20, 21 Recently, an increase in basal insulin concentrations was reported in knockout mice with lacking insulin receptor in pancreatic b-cells. 22 This ®nding suggests that insulin resistance in b-cells may contribute to fasting hyperinsulinemia. In obese humans some studies have reported a lack of insulin feedback, 17, 19 whereas others have observed a level of inhibition similar to that in lean subjects following insulin infusion. 23, 24 The extent of obesity andaor the magnitude of insulin resistance may be important factors in explaining these differences.
Since the morbidly obese usually show a severe peripheral insulin resistance, the present study was designed to examine the impact of experimentally induced hyperinsulinemia under euglycemic conditions on insulin secretion in this group of individuals compared to healthy, ideal weight subjects.
Material and methods

Study population
Twelve obese subjects (eight women and four men) and 16 lean control subjects (10 women and six men) were studied. None of the subjects had lost weight or changed their dietary habits during the 6 months preceding the study. The anthropometric characteristics are given in Table 1 . All subjects had normal resting arterial blood pressure levels, as de®ned by JNC V (systolic`140 mmHg and diastolic`90 mmHg), 25 and normal glucose tolerance in an oral glucose tolerance test (OGTT) according to the National Diabetes Data Group criteria. 26 None of the subjects were on any medication which could in¯uence insulin secretion and sensitivity. All subjects had normal liver and renal function tests. Morbid obesity was de®ned as a body mass index (BMI) ! 40 kgam 2 . The investigation was approved by the Institutional Review Board of the Faculty of Medical Sciences (UNICAMP), and all subjects gave informed consent before the study began.
Experimental protocol
Body composition was evaluated by electrical bioimpedance 27 using a Biodynamics monitor. The waist was measured at the umbilicus level and the hip at the larger buttock circumference point. Each subject received an OGTT and a euglycemic insulin clamp on different days, approximately 1 week apart. Arterial blood pressure was measured by mercury sphygmomanometry (a large cuff was used in obese individuals). For the OGTT, 40 gam 2 of glucose was ingested over 5 min, and venous blood was sampled at 30 min intervals over 2 h for plasma glucose and insulin measurements. The clamp study, which was done after an overnight fast (12 ± 14 h), consisted of 2 h of euglycemic insulin infusion at a rate of 280 pmolaminam 2 of body surface area. 28 A polyethylene, 20-gage catheter was inserted into an antecubital vein for the infusion of insulin and glucose. Another catheter was inserted retrogradely into a wrist vein, and the hand placed in a heated box ( $ 60 C) to allow the sampling of arterialized blood. 29 The 2 h before the start of the insulin infusion constituted the basal period. During the basal period and the insulin clamp, indirect calorimetry was done using a computerized, continuous open-circuit system with a canopy (Metabolic Cart Horizon, Vmax SensorMedics). Throughout the study protocol, patency of the sampling catheter was maintained by injecting 1 ml of saline after collecting each blood sample. During the insulin infusion, glucose was measured at 5 min intervals and plasma glucose was maintained with a variable glucose infusion. Venous samples for C-peptide and insulin measurements were obtained at 20 min intervals from time 20 min before until 2 h after starting the insulin infusion.
Analytical procedures
Plasma glucose was measured by the glucose oxidase technique in a Beckman glucose analyzer (Beckman, Fullerton, CA, USA). Plasma concentrations of insulin and C-peptide were measured by radioimmunoassay using a speci®c kit for human insulin (less than 0.2% cross-reactivity with proinsulin) and for C-peptide (Linco Research Inc., St Louis, MO, USA). Plasma uric acid, total cholesterol, HDL cholesterol and triglycerides were assayed spectrophotometrically on an automatic colorimetric system (Cobas Miras-Roche).
Data analysis
Whole-body glucose utilization (or M value) was calculated from the infusion rate of exogenous glucose (GIR) during the second hour of the insulin clamp period, after correction for changes in glucose levels in a distribution volume of 250 mlakg. The M value was normalized per kg of fat-free mass (mmolaminakg FFM). An index of insulin sensitivity (IS) was calculated as the ratio of the insulin-mediated glucose clearance rate ( M divided by steady-state plasma glucose level) to the steady-state plasma insulin concentration (log transformed). Areas under the OGTT time ± concentration curves were calculated by the trapezoidal rule. The posthepatic insulin clearance rate was calculated as the ratio of the insulin infusion rate to the difference between the steady-state plasma insulin concentration and the product of the fasting insulin level and the ratio between steadystate C-peptide and fasting C-peptide values (insulin clearance insulin infusion ratea(SSPIÀ(FPIÂSSPCPepa FPCpep))). 23, 30 The fasting posthepatic insulin delivery rate was obtained as the product of insulin clearance and the fasting plasma insulin concentration. 30 Post-OGTT Insulin b-cell inhibition in the morbidly obese E Muscelli et al posthepatic insulin delivery was calculated as the product of insulin clearance and the OGTT insulin area under the curve on the assumption that insulin clearance was unchanged during glucose absorption. 31 The insulinaglucose ratio was calculated as the ratio of post-OGTT insulin delivery to post-OGTT glucose area.
Statistical analysis
All data are given as the mean AE s.e.m. Comparison of the means was done using a paired or unpaired t-test as appropriate. Simple linear and stepwise regression analysis and Pearson partial correlation coef®cients were calculated using standard techniques. A P-value 0.05 indicated signi®cance.
Results
Anthropometric characteristics
The patients were morbidly obese, with a BMI of 54.8 AE 2.5 kgam 2 . The fat mass was very high in the obese group (about 45% of body weight) with a FFM of 82.9 AE 3.6 vs 49.2 AE 2.3 kg in the lean group (P`0.0001). The waist-to-hip ratio was also higher in the obese group (Table 1) .
Metabolic characteristics
All study subjects had a normal glucose tolerance and the area under the glucose curve during the OGTT was similar between the groups. On the other hand, fasting plasma insulin, fasting and post-OGTT insulin delivery, the area under the insulin curve, and the insulinaglucose ratio after glucose ingestion were all signi®cantly higher in the obese than in the lean controls. Serum uric acid and plasma triglycerides were signi®cantly higher in obese than in lean individuals (Table 2) .
Clamp data
Fasting plasma glucose levels were similar in the groups, and during the clamp varied 1.5 AE 1.2% andÀ1.9 AE 0.8% from the basal values in the obese and lean groups, respectively. For this reason, plasma glucose did not change signi®cantly during insulin infusion compared to the fasting state. Fasting insulin levels were signi®cantly higher in the obese (328 AE 94 vs 88 AE 4 pmolal, P 0.006) and increased to similar levels during the clamp period. IS (M value or insulin sensitivity index) was signi®cantly impaired in the obese: the insulinmediated glucose uptake normalized to FFM was about 40% of the lean glucose uptake (Table 3 and Figure 1 ). The insulin clearance was higher in obese than in lean subjects. Posthepatic insulin delivery was also higher in the former than in Figure 1 Glucose infusion rate during the euglycemic insulin clamp (P`0.0001; ANOVA for repeated measures). Plasma glucose levels (P NS; ANOVA for repeated measures).
Insulin b-cell inhibition in the morbidly obese E Muscelli et al the latter, both in the fasting state and following glucose ingestion (Tables 2 and 3 ). Fasting and steady-state plasma C-peptide levels were about three times higher in the obese compared to the lean group (Table 4 ). The percentage decrease throughout the insulin infusion period was lower in the obese (mean 0 ± 40 min: 10.8 AE 10.1% vs À31.0 AE 4.6%; mean 60 ± 120 min: À16.9 AE 6.9% vs À43.0 AE 5.6%, P`0.006; Figure  2A , B). The fasting C-peptide-to-insulin molar ratio was similar in both groups, but decreased less during insulin infusion in the obese. As a result, during the clamp period, the molar ratio was signi®cantly higher in these patients (Table 4) .
In the lean group, the percentage variation of C-peptide was related to MaFFM during the clamp time from 0 to 60 min (r 0.61, P 0.05) and during the clamp steadystate period (r 0.53, P 0.03; Figure 3 ). These correlations remained signi®cant even after adjustment for the glucose variation (Pearson partial correlation coef®cient: 0.53, P 0.03). There was no correlation between C-peptide levels and age, sex or glucose levels in either group. There was also no correlation between the C-peptide levels and IS in obese subjects.
Discussion
The obese patients in this study showed many expected metabolic abnormalities, including severe peripheral insulin resistance, increased insulin secretion, a higher rate of resting energy expenditure, and higher serum triglyceride and uric acid levels and lower HDL cholesterol. As demonstrated by Bonadonna et al, 6 the suppression of endogenous glucose release is virtually complete at the plasma insulin levels reached in our clamp experiments, regardless of the BMI. For this reason, IS was calculated taking into account only the glucose infusion rate, normalized to the FFM. Since the plasma insulin levels at steady-state were higher in the obese group, though not signi®cantly, the IS was also normalized to this parameter. However, the total amount of glucose Insulin b-cell inhibition in the morbidly obese E Muscelli et al disposed of under the in¯uence of insulin was 60% lower in obese than in lean subjects, after normalization to fat-free mass. Thus, although the increased lean mass of the obese provided a compensatory mechanism of glucose utilization, it was still very low in these patients. Insulin secretion during a fasting and during insulin infusion in the euglycemic clamp was assessed using the Cpeptide plasma levels and, during the OGTT, the posthepatic insulin delivery rate was calculated from the insulin clearance and the insulin area. C-peptide was chosen to evaluate insulin secretion because of their equivalent molar ratio secretion, the negligible hepatic extraction 32 and similar clearance in lean and obese subjects. 9 Regardless of the method used for calculation, insulin secretion was about three times higher in obese patients compared to lean subjects.
Insulin infusion under euglycemic conditions at steadystate inhibited its own secretion by about 43% in the lean. In the obese, this inhibition was blunted to about 17%. These differences were evident even in the ®rst 40 min of the clamp. De Fronzo et al 33 reported a 53% reduction in insulin secretion in lean subjects with plasma insulin levels of 25 mUaml, suggesting that the inhibition occurred at low doses of insulin infusion. No further effect was observed when the plasma insulin levels were increased. This ®nding suggests that the plasma insulin levels used in our study would produce a maximal response. At similar insulin infusion rates, this suppression could not be enhanced by the additional infusion of somatostatin. 34 The decrease in Cpeptide (percentage variation) in the lean group was related to the IS after correction for variations in the glucose levels. The correction for glucose levels was done to minimize the effects of these variations even after arterializing the venous blood by heating the hand and attempting to maintain plasma glucose near the fasting levels. The lack of a relationship between the decrease in C-peptide levels and the plasma glucose variations is noteworthy. In the obese group there was no relationship between C-peptide variations and IS, a ®nding re¯ected in the very similar responses (MaLBM and C-peptide variation) to insulin infusion in these patients.
A suppressive effect of insulin on its own secretion has been seen in some studies, 15, 35 but not in others. 16, 17 The failure to document a fall in basal insulin secretion could be attributable to modest increases in plasma glucose that would stimulate insulin secretion, although other mechanisms may be involved. Bratusch-Marrain and Waldha Èusl demonstrated that the glucose-induced insulin response in healthy subjects was unaltered by exogenous hyperinsulinemia. 35 Thus, the insulin effect on its own secretion may be more important in the fasting state. In the fasting state, the C-peptideainsulin molar ratio was similar in both groups and the amount of exogenous insulin infused was the same, so that a similar decrease was expected during the clamp. The blunted inhibition of insulin secretion could explain the elevated steady-state C-peptideainsulin molar ratio in the obese group. The plasma insulin levels reached during the clamp were slightly higher in the obese, and could be explained by a higher persistent endogenous secretion.
Posthepatic plasma insulin clearance is normal in moderately obese patients, 7, 12 but was higher in the obese in our study (Table 3) . Insulin clearance was not normalized to body weight or lean body mass, since insulin is not appreciably degraded by peripheral tissues, 31 and normalization can underestimate insulin clearance in the obese. When the insulin clearance was normalized to body surface area, the differences between groups were eliminated and the results obtained (data not shown) were similar to those described by Polonsky et al. 12 Another reason for the discrepancy with previous reports could be the type of obese subjects studied (morbidly obese, mean BMI % 55 kgam 2 vs moderately obese). Since the insulin clearance was not lower in the obese, it certainly did not contribute to the hyperinsulinemia of these patients, thus reinforcing the importance of insulin hypersecretion. Of interest was that the response of the b-cell to glucose (as expressed by the insulinaglucose ratio) was signi®cantly enhanced in obese patients, again demonstrating hypersecretion.
The mechanism by which an increase in insulin concentration inhibits insulin secretion is not completely understood. The consistently higher endogenous C-peptide levels in the obese under both basal and suppressed conditions, and the lower percentage decrease in these subjects could have resulted from increased b-cell mass andaor insulin resistance. However, the inhibition of glucose-stimulated insulin secretion by somatostatin is maintained in the obese, 36, 37 which suggests a speci®c defect in insulin feedback and insulin resistance. The effect of insulin on its own secretion may be indirect (neurally mediated) andaor direct, through an action of insulin on b-cells via the insulin signalling pathway. Boden et al 38 demonstrated that hyperinsulinemia decreased C-peptide concentrations in control subjects and in kidney transplant patients, but not in patients after combined pancreasakidney transplantation. Figure 3 Relationship between the variation in C-peptide levels during steady-state insulin infusion (mean 60 ± 120 min) and insulin sensitivity (as M, normalized for fat-free mass) for the lean group (r 0.53; P 0.03).
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The main difference between patients who received a kidney transplant and those who received a pancreas and kidney transplant was that in the latter the pancreas was denervated. These data suggest that the inhibition of pancreatic insulin secretion by hyperinsulinemia is neurally mediated. This conclusion agrees with data obtained by Stagner et al 39 in in situ-perfused, vascularly isolated but innervated canine pancreas preparations in which exogenously infused insulin produced a small suppression of C-peptide release, not seen in the completely isolated canine pancreas. Islets are innervated by sympathetic, parasympathetic and peptidergic nerves. Sympathetic and peptidergic nerves are viable candidates since their neurotransmitters, eg noradrenaline and galanin, suppress insulin secretion. In lean individuals, insulin activates the sympathetic system 40 and causes a sympathetic shift in the autonomic balance, 41 whereas in the obese, sympathetic activation during the clamp is blunted, 42, 43 despite its enhanced basal activity. Some components of the insulin signalling pathway are present in normal islet b-cells as shown by the expression of the insulin receptor and the insulin receptor substrates-1 and -2 (IRS-1, IRS-2) in rat pancreatic islets 44 and clonal b-cell lines. 45 The role of these proteins in insulin-mediated feedback of its own secretion or in insulin resistance in b-cells is unknown. However, in knockout mice lacking the insulin receptor in pancreatic b-cells, there is an increase in basal insulin concentrations at 6 months of age, 22 suggesting that insulin resistance in b-cells can contribute to fasting hyperinsulinemia. The pattern of regulation of the insulin signalling proteins in b-cells of obese patients is unknown, but in other tissues there is a widespread decrease in insulin receptor and insulin receptor substrates, and in their activation. 46 Although these proteins have a tissue-speci®c regulation, it is reasonable to speculate that a down-regulation of the insulin receptor and its substrates in the pancreas of morbidly obese patients may contribute to insulin resistance in b-cells of these patients.
In summary, the inhibition by insulin of its own secretion is blunted in insulin-resistant, morbidly obese patients, partially through an altered sensitivity to insulin. This alteration may have a role in the pathogenesis of fasting hyperinsulinemia in obese patients.
